We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


GATC Biotech Orders Europe’s First HiSeq 2000 for Commercial Use

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GATC Biotech Orders Europe’s First HiSeq 2000 for Commercial Use"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
GATC Biotech has announced the purchase of Illumina’s new HiSeq 2000 sequencing platform, which has officially been launched last week. This latest acquisition will further strengthen GATC Biotech’s current fleet of three GA IIx.

Initially, the company will employ the HiSeq 2000 to human genome sequencing projects from its customers in the pharmaceutical and medical research field. It will also make the system’s high data output available to the industrial and academic research community interested in the high throughput sequencing of larger eukaryotic genomes.

“Illumina’s HiSeq 2000 with the estimated output of 200 GB per run allows us to virtually sequence 60 human genomes at 1x coverage in a week. Being an Illumina CSPro certified service provider we are confident to have the system quickly installed and geared up for production,” says Peter Pohl, CEO of GATC Biotech.

The HiSeq 2000 sequencing system had just been launched by llumina Inc. on the occasion of the J.P. Morgan Healthcare Conference last week in San Diego.